Toronto - Delayed Quote CAD

Theratechnologies Inc. (TH.TO)

1.8500 -0.0400 (-2.12%)
At close: April 24 at 3:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
11/30/2023
11/30/2022
11/30/2021
11/30/2020
Total Revenue
81,764.0000
81,764.0000
80,057.0000
69,823.0000
66,053.0000
Cost of Revenue
19,635.0000
19,635.0000
26,279.0000
23,260.0000
26,902.0000
Gross Profit
62,129.0000
62,129.0000
53,778.0000
46,563.0000
39,151.0000
Operating Expense
72,756.0000
72,756.0000
93,686.0000
71,799.0000
57,108.0000
Operating Income
-10,627.0000
-10,627.0000
-39,908.0000
-25,236.0000
-17,957.0000
Net Non Operating Interest Income Expense
-10,588.0000
-10,588.0000
-6,216.0000
-5,500.0000
-5,103.0000
Other Income Expense
-2,321.0000
-2,321.0000
-670.0000
-926.0000
409.0000
Pretax Income
-23,536.0000
-23,536.0000
-46,794.0000
-31,662.0000
-22,651.0000
Tax Provision
421.0000
421.0000
443.0000
63.0000
16.0000
Net Income Common Stockholders
-23,957.0000
-23,957.0000
-47,237.0000
-31,725.0000
-22,667.0000
Diluted NI Available to Com Stockholders
-23,957.0000
-23,957.0000
-47,237.0000
-31,725.0000
-22,667.0000
Basic EPS
-1.23
-0.91
-1.98
-1.37
-1.16
Diluted EPS
-1.23
-0.91
-1.98
-1.37
-1.16
Basic Average Shares
24,128.6570
26,332.4290
23,813.3440
23,087.5570
19,247.9080
Diluted Average Shares
24,128.6570
26,332.4290
23,813.3440
23,087.5570
19,247.9080
Total Operating Income as Reported
-10,627.0000
-10,627.0000
-39,908.0000
-25,236.0000
-17,957.0000
Total Expenses
92,391.0000
92,391.0000
119,965.0000
95,059.0000
84,010.0000
Net Income from Continuing & Discontinued Operation
-23,957.0000
-23,957.0000
-47,237.0000
-31,725.0000
-22,667.0000
Normalized Income
-22,564.4000
-22,564.4000
-46,742.6070
-31,044.3900
-22,967.6150
Interest Income
769.0000
769.0000
316.0000
195.0000
299.0000
Interest Expense
10,361.0000
10,361.0000
6,497.0000
5,664.0000
5,362.0000
Net Interest Income
-10,588.0000
-10,588.0000
-6,216.0000
-5,500.0000
-5,103.0000
EBIT
-13,175.0000
-13,175.0000
-40,297.0000
-25,998.0000
-17,289.0000
EBITDA
-9,860.0000
-9,860.0000
-27,826.0000
-17,250.0000
-8,769.0000
Reconciled Cost of Revenue
19,635.0000
19,635.0000
26,279.0000
23,260.0000
26,902.0000
Reconciled Depreciation
3,315.0000
3,315.0000
12,471.0000
8,748.0000
8,520.0000
Net Income from Continuing Operation Net Minority Interest
-23,957.0000
-23,957.0000
-47,237.0000
-31,725.0000
-22,667.0000
Total Unusual Items Excluding Goodwill
-2,321.0000
-2,321.0000
-670.0000
-926.0000
409.0000
Total Unusual Items
-2,321.0000
-2,321.0000
-670.0000
-926.0000
409.0000
Normalized EBITDA
-7,539.0000
-7,539.0000
-27,156.0000
-16,324.0000
-9,178.0000
Tax Rate for Calcs
0.0004
0.0004
0.0003
0.0003
0.0003
Tax Effect of Unusual Items
-928.4000
-928.4000
-175.6070
-245.3900
108.3850
11/30/2020 - 8/6/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ONC.TO Oncolytics Biotech Inc.
1.4700
+2.80%
 
MDNA.TO Medicenna Therapeutics Corp.
1.9200
+23.87%
 
APS.TO Aptose Biosciences Inc.
1.6600
+0.61%
 
AEZS.TO Aeterna Zentaris Inc.
2.6600
0.00%
 
BCT.TO BriaCell Therapeutics Corp.
3.0000
-4.76%
 
MBX.TO Microbix Biosystems Inc.
0.3350
0.00%
 
KNBIF Kane Biotech Inc.
0.0898
0.00%
 
ANTX AN2 Therapeutics, Inc.
2.4000
+1.27%
 
HBP.TO Helix BioPharma Corp.
0.1950
+2.63%
 
ACOG.CN Alpha Cognition Inc.
0.6800
0.00%